103 products were found matching "K00254"!

Leflunomide is a synthetic isoxazol and a prodrug form of A-771726 (Cay-14404), a dihydroorotate dehydrogenase inhibitor. Leflunomide inhibits de novo pyrimidine synthesis to regulate T lymphocyte progression through the cell cycle. It inhibits proliferation and activation of T cells when used at concentrations of...

Brequinar is an inhibitor of dihydroorotate dehydrogenase (DHODH, IC50 = ~20 nM), the enzyme that converts dihydroorotate to orotate during de novo pyrimidine synthesis. Brequinar is selective for DHODH over a panel of greater than 400 kinases at 100 nM. It induces differentiation of ER-HoxA9, U937, and THP-1 cells...

BAY-2402234 is an inhibitor of dihydroorotate dehydrogenase (DHODH, IC50 = 1.2 nM). It induces upregulation of the cell differentiation marker CD11b in MOLM-13 and HEL acute myeloid leukemia (AML) cells (EC50s = 3.16 and 0.96 nM, respectively) and inhibits the proliferation of nine leukemia cell lines (IC50s =...

Dihydroorotate dehydrogenase (DHODH) is involved in pyrimidine nucleoside biosynthesis. DHODH inhibitors have value in autoimmune diseases as well as cancer and certain infections. Vidofludimus is an immunosuppressive drug that inhibits DHODH (IC50s = 0.134, 1.29, and 10.6 µM for human, rat, and mouse isoforms,...

A-771726 is an active metabolite of the prodrug leflunomide (Cay-14860) that inhibits dihydroorotate dehydrogenase (DHODH, IC50 = 0.23 µM). A-771726 inhibits the production of prostaglandin E2 (PGE2, Cay-14010) in TNF-alpha- or IL-1alpha-stimulated isolated human synoviocytes (IC50s = 7 and 3 µM, respectively). It...

ASLAN003 is an inhibitor of dihydroorotate dehydrogenase (DHODH, IC50 = 35 nM). It inhibits the proliferation of MOLM-14 and KG-1 acute myeloid leukemia (AML) cells (IC50s = 0.582 and 0.382 µM, respectively), as well as induces apoptosis in the same cells when used at concentrations of 0.5 and 1 µM. ASLAN003 (1, 2,...

Leflunomide is a pyrimidine biosynthesis inhibitor. It is an established disease-modifying antirheumatic drug. It has been approved for treatment of rheumatoid arthritis (RA) and may also be useful in treating patients with Felty´s syndrome. It is suggested that supression of TNF signalling is one of the...

ML-390 is an inhibitor of dihydroorotate dehydrogenase (DHODH), the enzyme that converts dihydroorotate to orotate during de novo pyrimidine synthesis. In acute myeloid leukemia, leukemic myeloblast development is halted at an immature stage leading to perpetual self-renewal rather than differentiation. ML-390...

Leflunomide-d4 is intended for use as an internal standard for the quantification of leflunomide (Cay-14860) by GC- or LC-MS. Leflunomide is a synthetic isoxazol and a prodrug form of A-771726 (Cay-14404), a dihydroorotate dehydrogenase inhibitor. Leflunomide inhibits de novo pyrimidine synthesis to regulate T...

Protein function: Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor. [The UniProt Consortium]

Protein function: Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor. [The UniProt Consortium]

Protein function: Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor. [The UniProt Consortium] Buffer: 40% glycerol and PBS (pH 7.2). 0.02% sodium azide is added as preservative. Highest antigen sequence identity to mouse: 88% and to rat: 90%